

Cervical Cancer: A Summary of the Diagnostic and Risk Factors

Vandna sharma (Assistant professor Allied health sciences) Universal group of institutions

Author 1 **Dr Vikas Sharma** Principal UIMT, Universal group of institutions

Author 2 **Ruqia Ashraf** student, Universal group of institutions

Author 3 **Shakir Fayaz Wani**, Universal group of institutions

Author 4 **Owais Majeed**, Universal group of institutions

Author 5 **Aqib Mustaq**, Universal group of institutions

Author 6 **Shahid Ayoub Bhat**, Universal group of institutions

Author 7 **Arsalan Nabi Raina**, Universal group of institutions

Abstract

Millions of people worldwide are impacted by breast cancer, which is still a complicated and common health issue. This review article provides a thorough examination of the complex field of breast cancer, clarifying the wide range of risk factors that contribute to its development and investigating developments in diagnostic techniques. Numerous risk factors, including genetic predispositions such BRCA mutations, hormonal impacts, lifestyle factors, and reproductive patterns, have been found through a thorough review of recent literature. The complex tapestry of breast cancer etiology also includes age, family history, and environmental variables. Additionally, this study outlines the critical role that diagnostic technologies have in the early detection and treatment of breast cancer.

Keywords: risk factors, diagnosis, mortality, breast cancer, and cancer

1 Introduction

Breast cancer is one of the many and common malignant tumors that harm women. Numerous internal and external variables contribute to the development and occurrence of breast cancer. It is associated with poor lifestyle choices, environmental variables, and social-psychological issues. It has been shown that genetic mutations and family history account for 5% to 10% of breast cancer cases, whereas potentially modifiable factors account for 20% to 30% of cases. Breast cancer originates in breast cells. A malignant tumor is a group of cancer cells that can migrate into and damage surrounding tissue.

However, alterations to breast cells can sometimes lead to breast cancer. The cells lining the ducts—the tubes that transport milk from the glands to the nipple—are usually where breast cancer starts. This kind of breast cancer is called ductal carcinoma. Cancer can also develop from the cells of the lobules, which are groups of glands that produce milk. This kind of cancer is called lobular carcinoma. Ductal and lobular carcinomas can both be in situ, which indicates that the cancer has not migrated to other tissues and is still present in the original site. Additionally, they could be invasive, meaning they have penetrated the surrounding tissues. Less prevalent kinds of breast cancer can also appear. These include inflammatory breast cancer, breast Paget disease, and triple-negative breast cancer. Uncommon types of breast cancer include soft tissue sarcoma and non-Hodgkin lymphoma. China has a low rate of breast cancer, but research indicates that it has been gradually increasing. By 2022, there will be 2.5 million Chinese women between the ages of 35 and 49 who have the condition, with more than 100 cases per 100,000. Researching risk factors for breast cancer is therefore essential to reducing the disease's incidence. The most common cancer in women worldwide is breast cancer.

2. Women's risk factors for breast cancer

2.1. Individual breast cancer history

Women who have already had breast cancer are more likely to have it again. The second breast cancer may develop in a different breast or in the same breast as the first. Women with ductal carcinoma in situ or lobular carcinoma in situ breast cancers are more likely to experience a recurrence, even if most of them do not.

2.2. A family history of breast and other cancers

A family history of breast cancer is indicated if one or more close blood relatives have the disease. In certain families, there are more cases of breast cancer than one may expect. Determining whether a family's history of cancer is due to genes passed down from parents to children, a shared lifestyle, happenstance, or a combination of these factors can be challenging.

2.3 Big breasts

Dense breasts feature more connective tissue, glands, and milk ducts than fatty tissue. A hereditary characteristic is breast density. Women with dense breast tissue are more likely to develop breast cancer than those with little or no dense breast tissue. Only a mammography can identify breast density, however thick breasts can complicate the interpretation of the image. Dense tissue, such as malignancies, shows white on a mammography, whereas fatty tissue, which hides a tumor, appears black.

3. Breast cancer in women: Diagnosed through appended technologies

Due to ductal hyperproliferation, which is thereafter continuously encouraged by a variety of carcinogenic stimuli, breast tumors usually begin as benign tumors or even meta-static carcinomas. Depending on the tumor's microenvironment, such as stromal influences or macrophages, breast cancer can develop and progress in different ways. Neoplasms might be generated when carcinogens were only exposed to the rat mammary gland's stroma, not the extracellular matrix or the epithelium. Macrophages have the ability to produce a mutagenic inflammatory milieu that promotes angiogenesis and shields cancer cells from immunological rejection.

Two specific ideas about the initiation and spread of breast cancer are the stochastic theory and the CSC theory. All tumor subtypes are descended from the same stem cells or transit-amplifying cells, according to the notion regarding CSCs. Acquired genetic and epigenetic alterations in stem cells or progenitor cells result in a range of tumor characteristics. The stochastic theory states that all tumor subtypes originate from a single type of cell. Random mutations can occur in any breast cell over time, and after a sufficient number of these mutations have accumulated, the breast cell can become a tumor cell.

4. Prevention of breast cancer through biology

Monoclonal antibodies for the disease, a type of biological prophylaxis, have recently been created to improve the quality of life for individuals with breast cancer. Human epidermal growth factor receptor 2 (HER2) is one of the main targets of these monoclonal antibodies. In 20% to 30% of cases of breast cancer, the HER2 gene is amplified or the HER2 protein is overexpressed. The FDA approved trastuzumab (Herceptin), a recombinant humanized monoclonal antibody, as the first HER2-targeted medication. In the extracellular area of HER2, it can directly connect with the C-terminal region of domain IV. The exact mechanism of trastuzumab's anti-tumor action is still unknown.

5. Women are diagnosed with breast cancer

5.1. Mammography

Low radiation doses are used in diagnostic mammography, an x-ray that produces a picture of the breast. It is used to monitor unexpected results from screening mammograms or clinical breast exams. Mammography can also be used to find an abnormal spot during a biopsy.

5.2. Ultrasound

An ultrasound uses high-frequency sound waves to produce images of different bodily parts. It is used to identify if a breast bulge is a cyst or a solid tumor. Medical practitioners can also use ultrasonography to guide patients to the biopsy site. Women with advanced breast cancer may get an ultrasound to check for liver metastases.

5.3. Biopsy

A biopsy is the only reliable way to diagnose breast cancer. A biopsy is performed to extract tissues or cells from the patient's body for analysis in a lab. Whether or not cancer cells were found in the sample will be determined by the pathologist's report. Whether the lump is palpable—that is, you can feel it—or non-palpable—that is, you cannot—will determine the type of biopsy that is carried out. The doctor may use mammography or ultrasound to identify the area that needs to be checked.

5.4 The biopsy of the core

A unique hollow needle is used to remove bodily tissue during the core biopsy. It is used by physicians to collect a sample from a suspicious breast region. During the process, they could gather a lot of samples from the local area. In order to remove more tissue with the hollow needle, surgeons may use a specific vacuum. We refer to this method as vacuum-assisted core biopsy.

5.5. A biopsy of lymph nodes

A lymph node biopsy is a surgical technique in which lymph nodes are removed so they can be inspected under a microscope to check for malignancy. Breast cancer cells have the ability to detach from the tumor and travel via the lymphatic system. They may initially spread to the lymph nodes under the arm. Doctors count the number of lymph nodes that have breast cancer in order to assist establish the disease's stage.

6 Preventative measures and ongoing research efforts

Certainly, preventive measures and ongoing research efforts are crucial components in the fight against breast cancer.

7. Preventive actions

Promoting routine screenings and mammograms for women depending on age and risk factors can help with early detection and improve treatment results.

The chance of developing breast cancer can be decreased by encouraging a healthy lifestyle that includes eating a balanced diet, exercising frequently, consuming less alcohol, abstaining from smoking, and maintaining a healthy weight. As a preventive measure, breastfeeding should be encouraged since it has been demonstrated to have protective effects against breast cancer.

Providing comprehensive and accessible education on breast cancer risks, symptoms, and the importance of early detection can empower individuals to take proactive measures and seek timely medical attention. For individuals with a family history or known genetic mutations (like BRCA1 or BRCA2), genetic counseling and testing can help in assessing risks and making informed decisions about preventive measures.

8. Ongoing studies

Targeted medicines, which concentrate on particular genetic abnormalities or molecular markers linked to breast cancer, are being developed by researchers to increase therapeutic efficacy while lowering adverse effects. There is an ongoing study on the use of immunotherapy, which uses the body's immune system to target cancer cells, in the treatment of breast cancer. In order to provide an earlier and more precise diagnosis, ongoing research attempts to create screening techniques that are more sensitive and specific than mammography, such as molecular imaging and blood-based biomarkers. Understanding individual susceptibility and developing new therapeutic targets are made possible by researching the genetic and epigenetic variables that influence the development of breast cancer. The goal of research is to find more lifestyle changes, drugs, or treatments that can lower the risk of breast cancer. In order to improve treatment outcomes worldwide and further our understanding of breast cancer, collaborative research initiatives between nations and institutions seek to exchange data, resources, and expertise. The goal is to lower the incidence, morbidity, and death of breast cancer globally by prioritizing prevention via lifestyle changes, early diagnosis through efficient screening, and funding state-of-the-art research.

9. Conclusion

Breast cancer continues to be a major worldwide health issue, affecting millions of people annually. The many risk factors and diagnostic techniques that are essential to comprehending and treating breast cancer have been highlighted in this review, underscoring the disease's complexity. Moreover, advancements in diagnostic techniques have significantly improved early detection and treatment outcomes. Mammography is essential for detecting breast cancer in its early stages, allowing for timely intervention and potentially improving patient prognoses. It works in tandem with new technologies such as magnetic resonance imaging and molecular testing. Going forward, it will be crucial to keep researching new risk factors, improving screening techniques, and creating focused treatments.

References

- [1] Obeagu EI, Babar Q, Vincent CC, et al. Therapeutic targets in breast cancer signaling: a review. *J Pharm Res Int.* 2021;33:82–99.
- [2] Aizaz M, Khan M, Khan FI, et al. Burden of breast cancer: developing countries perspective. *Int J Innov Appl Res.* 2023;11:31–7.
- [3] Ibekwe AM, Obeagu EI, Ibekwe CE, et al. Challenges of exclusive breastfeeding among working class women in a teaching hospital South East, Nigeria. *J Pharm Res Int.* 2022;34:1.
- [4] Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. *Int J Biol Sci.* 2017;13:1387–97.
- [5] Sinha T. Tumors: benign and malignant. *Cancer Ther Oncol Int J.* 2018;10:555790.
- [6] Edward U, Obeagu EI, Okorie HM, et al. Studies of serum calcium, inorganic phosphate, and magnesium levels in lactating mothers in Owerri. *J Pharm Res Int.* 2021;33:209–16.
- [7] Obeagu EI, Ahmed YA, Obeagu GU, et al. Biomarkers of breast cancer: overview. *Int J Curr Res Biol Med.* 2023;8:8–16.
- [8] Iatrakis G, Zervoudis S. Epidemiology of ductal carcinoma in situ. *Chirurgia (Romania).* 2021;116(5 Suppl):S15–S21.
- [9] Jaggi R, Mason G, Overmoyer BA, et al. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. *Breast Cancer Res Treat.* 2022;192:235–43.
- [10] Pedersen RN, Esen BO, Mellekjær L, et al. The incidence of breast cancer recurrence 10–32 years after primary diagnosis. *J Natl Cancer Inst.* 2022;114:391–99.
- [11] Xia C, Dong X, Li H, et al. Cancer statistics in China and the United States, 2022: profiles, trends, and determinants. *Chin Med J (Engl).* 2022;135:584–90.
- [12] Mahdavi M, Nassiri M, Kooshyar MM, et al. Hereditary breast cancer; genetic penetrance and current status with BRCA. *J Cell Physiol.* 2019;234:5741–50.

- [13] Liu H, Shi S, Gao J, et al. Analysis of risk factors associated with breast cancer in women: a systematic review and meta-analysis. *Transl Cancer Res.* 2022;11:1344–53.
- [14] Heer E, Ruan Y, Mealey N, et al. The incidence of breast cancer in Canada 1971-2015: trends in screening-eligible and young-onset age groups. *Can J Public Health.* 2020;111:787–93.
- [15] Van Ourti T, O'Donnell O, Koç H, et al. Effect of screening mammography on breast cancer mortality: Quasi-experimental evidence from the rollout of the Dutch population-based program with 17-year follow-up of a cohort. *Int J Cancer.* 2020;146:2201–8.
- [16] Buist DSM, Abraham L, Lee CI, et al. Breast biopsy intensity and findings following breast cancer screening in women with and without a personal history of breast cancer. *JAMA Intern Med.* 2018;178:458–68.
- [17] Maio F, Tari DU, Granata V, et al. Breast cancer screening during COVID-19 emergency: patients and department management in a local experience. *J Pers Med.* 2021;11:380.
- [18] Li MR, Liu MZ, Ge YQ, et al. Assistance by routine CT features combined with 3D texture analysis in the diagnosis of BRCA gene mutation status in advanced epithelial ovarian cancer. *Front Oncol.* 2021;11:696780.
- [19] Hu X, Zhang Q, Xing W, et al. Role of microRNA/lncRNA intertwined with the Wnt/ β -Catenin axis in regulating the pathogenesis of triple-negative breast cancer. *Front Pharmacol.* 2022;13:814971.
- [20] Thigpen D, Kappler A, Brem R. The role of ultrasound in screening dense breasts—a review of the literature and practical solutions for implementation. *Diagnostics.* 2018;8:20.
- [21] Vatankhah H, Khalili P, Vatanparast M, et al. Prevalence of early and late menopause and its determinants in Rafsanjan cohort study. *Sci Rep.* 2023;13:1847.
- [22] Garnæs KK, Elvebakk T, Salvesen O, et al. Dietary intake in early pregnancy and glycemia in late pregnancy among women with obesity. *Nutrients.* 2022;14:105.
- [23] Mills ZB, Faull RLM, Kwakowsky A. Is hormone replacement therapy a risk factor or a therapeutic option for Alzheimer's disease? *Int J Mol Sci.* 2023;24:3205.
- [24] Kunyhamu MS, Daud A, Jusoh N. Obesity among health-care workers: which occupations are at higher risk of being obese? *Int J Environ Res Public Health.* 2021;18:4381.
- [25] Belachew EB, Sewasew DT. Molecular mechanisms of endocrine resistance in estrogen-positive breast cancer. *Front Endocrinol.* 2021;12:689705.
- [26] Kim M, Jung MS. Effects of chemotherapy-induced peripheral neuropathy in women with breast cancer: a structural equation approach with the theory of unpleasant symptoms. *Cancer Nurs.* 2021;44:145–53.
- [27] Chang CC, Ho TC, Lien CY, et al. The effects of prior mammography screening on the performance of breast cancer detection in Taiwan. *Healthcare (Basel).* 2022;10:1037.